Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McKesson Corporation (MCK) vs S&P500 ETF (SPY) Price & Performance

McKesson CorporationTrade
S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

McKesson Corporation vs S&P500 ETF — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while S&P500 ETF trades at $776.46 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 7.6× McKesson Corporation's market cap, and McKesson Corporation pays a 0.4% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and S&P500 ETF for 205 Days on average.

MCKSPY
Market Cap
$108.46B$821.54B
Volume
712,60740,070,358
Sector
Health—
52-Week High
$995.69$779.14
52-Week Low
$725.17$631.99
Typical Hold Time
74 Days205 Days
Enterprise Value
$115.00B—
Dividend Yield
0.4%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McKesson Corporation

McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.

MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.

S&P500 ETF

SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF is near its pivot point of $776, with immediate resistance at $779. Recent news highlights mixed sentiment, with some articles pointing to strong corporate earnings growth in 2026 but expected deceleration in 2027, while others discuss defensive positioning and valuation concerns.

The outlook for SPY is cautiously optimistic, supported by bullish technical trends and robust earnings growth projections for 2026. Key risks include potential profit growth slowdown in 2027, elevated market valuations, and macroeconomic headwinds such as rising Treasury yields. Investors should weigh the ETF's broad market exposure against these factors for long-term positioning.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MCK
40% Buy60% Sell
Avg holding period · 74 Days
SPY
75% Buy25% Sell
Avg holding period · 205 Days

Top news

Latest headlines on both assets

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK →

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY →